APO Research
Talk to an analyst

APO RESEARCH · REPORT

Innovations in Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Innovations in Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchInnovations in Biologics and Biosimilars Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Innovations in Biologics and Biosimilars Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Innovations in Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Innovations in Biologics and Biosimilars Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Innovations in Biologics and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Innovations in Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Innovations in Biologics and Biosimilars include Changchun High Tech, Tonghua Dongbao, Sobi, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Innovations in Biologics and Biosimilars market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Innovations in Biologics and Biosimilars and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Innovations in Biologics and Biosimilars revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Innovations in Biologics and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Innovations in Biologics and Biosimilars Segment by Company

Changchun High Tech

Tonghua Dongbao

Sobi

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

Kanghong Pharma

Biogen

Amgen

AbbVie

United Laboratory

Innovent Biologics

Gan&Lee

Celltrion

3SBIO

Innovations in Biologics and Biosimilars Segment by Type

Vaccines

Insulin

Interferon

Monoclonal Antibodies

Others

Innovations in Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Innovations in Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Innovations in Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Innovations in Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Innovations in Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Innovations in Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Innovations in Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Innovations in Biologics and Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Innovations in Biologics and Biosimilarsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Vaccines Table 3. Key Players of Insulin Table 4. Key Players of Interferon Table 3. Key Players of Monoclonal Antibodies Table 4. Key Players of Others Table 5. Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospital Table 7. Key Players of Retail Pharmacy Table 8. Key Players of Other Table 9. Global Innovations in Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Innovations in Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Innovations in Biologics and Biosimilars Market Share by Region (2021-2026) Table 12. Global Innovations in Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Innovations in Biologics and Biosimilars Market Share by Region (2027-2032) Table 14. Innovations in Biologics and Biosimilars Industry Trends Table 15. Innovations in Biologics and Biosimilars Industry Drivers Table 16. Innovations in Biologics and Biosimilars Industry Opportunities and Challenges Table 17. Innovations in Biologics and Biosimilars Industry Restraints Table 18. Global Innovations in Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Innovations in Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 20. Global Innovations in Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Innovations in Biologics and Biosimilars Key Company Head Office and Area Served Table 22. Global Innovations in Biologics and Biosimilars Company, Product Type & Application Table 23. Global Innovations in Biologics and Biosimilars Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Innovations in Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Innovations in Biologics and Biosimilars Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Innovations in Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 30. Global Innovations in Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 31. Global Innovations in Biologics and Biosimilars Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Innovations in Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 35. Global Innovations in Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 36. Changchun High Tech Company Information Table 37. Changchun High Tech Business Overview Table 38. Changchun High Tech Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Changchun High Tech Innovations in Biologics and Biosimilars Product Portfolio Table 40. Changchun High Tech Recent Development Table 41. Tonghua Dongbao Company Information Table 42. Tonghua Dongbao Business Overview Table 43. Tonghua Dongbao Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Tonghua Dongbao Innovations in Biologics and Biosimilars Product Portfolio Table 45. Tonghua Dongbao Recent Development Table 46. Sobi Company Information Table 47. Sobi Business Overview Table 48. Sobi Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sobi Innovations in Biologics and Biosimilars Product Portfolio Table 50. Sobi Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Sanofi Innovations in Biologics and Biosimilars Product Portfolio Table 55. Sanofi Recent Development Table 56. Johnson & Johnson Company Information Table 57. Johnson & Johnson Business Overview Table 58. Johnson & Johnson Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Johnson & Johnson Innovations in Biologics and Biosimilars Product Portfolio Table 60. Johnson & Johnson Recent Development Table 61. Novartis Company Information Table 62. Novartis Business Overview Table 63. Novartis Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Novartis Innovations in Biologics and Biosimilars Product Portfolio Table 65. Novartis Recent Development Table 66. Novo Nordisk Company Information Table 67. Novo Nordisk Business Overview Table 68. Novo Nordisk Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Novo Nordisk Innovations in Biologics and Biosimilars Product Portfolio Table 70. Novo Nordisk Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Merck Innovations in Biologics and Biosimilars Product Portfolio Table 75. Merck Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Roche Innovations in Biologics and Biosimilars Product Portfolio Table 80. Roche Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eli Lilly Innovations in Biologics and Biosimilars Product Portfolio Table 85. Eli Lilly Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Pfizer Innovations in Biologics and Biosimilars Product Portfolio Table 90. Pfizer Recent Development Table 91. Kanghong Pharma Company Information Table 92. Kanghong Pharma Business Overview Table 93. Kanghong Pharma Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Kanghong Pharma Innovations in Biologics and Biosimilars Product Portfolio Table 95. Kanghong Pharma Recent Development Table 96. Biogen Company Information Table 97. Biogen Business Overview Table 98. Biogen Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Biogen Innovations in Biologics and Biosimilars Product Portfolio Table 100. Biogen Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Amgen Innovations in Biologics and Biosimilars Product Portfolio Table 105. Amgen Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. AbbVie Innovations in Biologics and Biosimilars Product Portfolio Table 110. AbbVie Recent Development Table 111. United Laboratory Company Information Table 112. United Laboratory Business Overview Table 113. United Laboratory Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. United Laboratory Innovations in Biologics and Biosimilars Product Portfolio Table 115. United Laboratory Recent Development Table 116. Innovent Biologics Company Information Table 117. Innovent Biologics Business Overview Table 118. Innovent Biologics Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Innovent Biologics Innovations in Biologics and Biosimilars Product Portfolio Table 120. Innovent Biologics Recent Development Table 121. Gan&Lee Company Information Table 122. Gan&Lee Business Overview Table 123. Gan&Lee Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Gan&Lee Innovations in Biologics and Biosimilars Product Portfolio Table 125. Gan&Lee Recent Development Table 126. Celltrion Company Information Table 127. Celltrion Business Overview Table 128. Celltrion Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Celltrion Innovations in Biologics and Biosimilars Product Portfolio Table 130. Celltrion Recent Development Table 131. 3SBIO Company Information Table 132. 3SBIO Business Overview Table 133. 3SBIO Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. 3SBIO Innovations in Biologics and Biosimilars Product Portfolio Table 135. 3SBIO Recent Development Table 136. North America Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 137. North America Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 138. North America Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 139. North America Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 140. North America Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. North America Innovations in Biologics and Biosimilars Market Size by Country (2021-2026) Table 142. North America Innovations in Biologics and Biosimilars Market Size by Country (2027-2032) Table 143. Europe Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 144. Europe Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 145. Europe Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 146. Europe Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 147. Europe Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Innovations in Biologics and Biosimilars Market Size by Country (2021-2026) Table 149. Europe Innovations in Biologics and Biosimilars Market Size by Country (2027-2032) Table 150. China Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 151. China Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 152. China Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 153. China Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 154. Asia Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 155. Asia Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 156. Asia Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 157. Asia Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 158. Asia Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Innovations in Biologics and Biosimilars Market Size by Country (2021-2026) Table 160. Asia Innovations in Biologics and Biosimilars Market Size by Country (2027-2032) Table 161. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 162. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 163. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 164. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 165. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2021-2026) Table 167. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Innovations in Biologics and Biosimilars Product Image Figure 2. Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Innovations in Biologics and Biosimilars Market Share by Type: 2025 VS 2032 Figure 4. Vaccines Image Figure 5. Insulin Image Figure 6. Interferon Image Figure 7. Monoclonal Antibodies Image Figure 8. Others Image Figure 9. Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Innovations in Biologics and Biosimilars Market Share by Application: 2025 VS 2032 Figure 11. Hospital Image Figure 12. Retail Pharmacy Image Figure 13. Other Image Figure 14. Global Innovations in Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 16. Global Innovations in Biologics and Biosimilars Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Innovations in Biologics and Biosimilars Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Innovations in Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Innovations in Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Innovations in Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 23. Global Innovations in Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Innovations in Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 25. North America Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 26. North America Innovations in Biologics and Biosimilars Market Share by Type (2021-2032) Figure 27. North America Innovations in Biologics and Biosimilars Market Share by Application (2021-2032) Figure 28. North America Innovations in Biologics and Biosimilars Market Share by Country (2021-2032) Figure 29. United States Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 30. Canada Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 32. Europe Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 33. Europe Innovations in Biologics and Biosimilars Market Share by Type (2021-2032) Figure 34. Europe Innovations in Biologics and Biosimilars Market Share by Application (2021-2032) Figure 35. Europe Innovations in Biologics and Biosimilars Market Share by Country (2021-2032) Figure 36. Germany Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 37. France Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 39. Italy Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 40. Russia Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 42. China Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 43. China Innovations in Biologics and Biosimilars Market Share by Type (2021-2032) Figure 44. China Innovations in Biologics and Biosimilars Market Share by Application (2021-2032) Figure 45. Asia Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 46. Asia Innovations in Biologics and Biosimilars Market Share by Type (2021-2032) Figure 47. Asia Innovations in Biologics and Biosimilars Market Share by Application (2021-2032) Figure 48. Asia Innovations in Biologics and Biosimilars Market Share by Country (2021-2032) Figure 49. Japan Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 53. India Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 54. Australia Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Country (2021-2032) Figure 59. Brazil Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 64. UAE Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 66. Chile Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Insulin
  • Interferon
  • Monoclonal Antibodies
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Changchun High Tech
  • Tonghua Dongbao
  • Sobi
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Kanghong Pharma
  • Biogen
  • Amgen
  • AbbVie
  • United Laboratory
  • Innovent Biologics
  • Gan&Lee
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccines
  5. 1.2.3 Insulin
  6. 1.2.4 Interferon
  7. 1.2.5 Monoclonal Antibodies
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Innovations in Biologics and Biosimilars Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Retail Pharmacy
  13. 1.3.4 Other
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Innovations in Biologics and Biosimilars Growth Trends by Region
  16. 1.5.1 Global Innovations in Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Innovations in Biologics and Biosimilars Market Size by Region (2021-2026)
  18. 1.5.3 Innovations in Biologics and Biosimilars Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Innovations in Biologics and Biosimilars Market Dynamics
  1. 2.1 Innovations in Biologics and Biosimilars Industry Trends
  2. 2.2 Innovations in Biologics and Biosimilars Industry Drivers
  3. 2.3 Innovations in Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Innovations in Biologics and Biosimilars Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Innovations in Biologics and Biosimilars Revenue by Company (2021-2026)
  2. 3.2 Global Innovations in Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Innovations in Biologics and Biosimilars Key Company Head office and Area Served
  4. 3.4 Global Innovations in Biologics and Biosimilars Company, Product Type & Application
  5. 3.5 Global Innovations in Biologics and Biosimilars Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Innovations in Biologics and Biosimilars Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Innovations in Biologics and Biosimilars Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Innovations in Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Innovations in Biologics and Biosimilars Market by Type
  1. 4.1 Global Innovations in Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Innovations in Biologics and Biosimilars Market Size by Type (2021-2032)
  3. 4.3 Global Innovations in Biologics and Biosimilars Market Size Share by Type (2021-2032)
5 Innovations in Biologics and Biosimilars Market by Application
  1. 5.1 Global Innovations in Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Innovations in Biologics and Biosimilars Market Size by Application (2021-2032)
  3. 5.3 Global Innovations in Biologics and Biosimilars Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Changchun High Tech
  2. 6.1.1 Changchun High Tech Company Information
  3. 6.1.2 Changchun High Tech Business Overview
  4. 6.1.3 Changchun High Tech Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Changchun High Tech Innovations in Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Changchun High Tech Recent Developments
  7. 6.2 Tonghua Dongbao
  8. 6.2.1 Tonghua Dongbao Company Information
  9. 6.2.2 Tonghua Dongbao Business Overview
  10. 6.2.3 Tonghua Dongbao Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Tonghua Dongbao Innovations in Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Tonghua Dongbao Recent Developments
  13. 6.3 Sobi
  14. 6.3.1 Sobi Company Information
  15. 6.3.2 Sobi Business Overview
  16. 6.3.3 Sobi Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Sobi Innovations in Biologics and Biosimilars Product Portfolio
  18. 6.3.5 Sobi Recent Developments
  19. 6.4 Sanofi
  20. 6.4.1 Sanofi Company Information
  21. 6.4.2 Sanofi Business Overview
  22. 6.4.3 Sanofi Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Sanofi Innovations in Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Sanofi Recent Developments
  25. 6.5 Johnson & Johnson
  26. 6.5.1 Johnson & Johnson Company Information
  27. 6.5.2 Johnson & Johnson Business Overview
  28. 6.5.3 Johnson & Johnson Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Johnson & Johnson Innovations in Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Johnson & Johnson Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Novartis Innovations in Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Novo Nordisk
  38. 6.7.1 Novo Nordisk Company Information
  39. 6.7.2 Novo Nordisk Business Overview
  40. 6.7.3 Novo Nordisk Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Novo Nordisk Innovations in Biologics and Biosimilars Product Portfolio
  42. 6.7.5 Novo Nordisk Recent Developments
  43. 6.8 Merck
  44. 6.8.1 Merck Company Information
  45. 6.8.2 Merck Business Overview
  46. 6.8.3 Merck Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Merck Innovations in Biologics and Biosimilars Product Portfolio
  48. 6.8.5 Merck Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Roche Innovations in Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Eli Lilly
  56. 6.10.1 Eli Lilly Company Information
  57. 6.10.2 Eli Lilly Business Overview
  58. 6.10.3 Eli Lilly Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Eli Lilly Innovations in Biologics and Biosimilars Product Portfolio
  60. 6.10.5 Eli Lilly Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Pfizer Innovations in Biologics and Biosimilars Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Kanghong Pharma
  68. 6.12.1 Kanghong Pharma Company Information
  69. 6.12.2 Kanghong Pharma Business Overview
  70. 6.12.3 Kanghong Pharma Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Kanghong Pharma Innovations in Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Kanghong Pharma Recent Developments
  73. 6.13 Biogen
  74. 6.13.1 Biogen Company Information
  75. 6.13.2 Biogen Business Overview
  76. 6.13.3 Biogen Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Biogen Innovations in Biologics and Biosimilars Product Portfolio
  78. 6.13.5 Biogen Recent Developments
  79. 6.14 Amgen
  80. 6.14.1 Amgen Company Information
  81. 6.14.2 Amgen Business Overview
  82. 6.14.3 Amgen Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Amgen Innovations in Biologics and Biosimilars Product Portfolio
  84. 6.14.5 Amgen Recent Developments
  85. 6.15 AbbVie
  86. 6.15.1 AbbVie Company Information
  87. 6.15.2 AbbVie Business Overview
  88. 6.15.3 AbbVie Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 AbbVie Innovations in Biologics and Biosimilars Product Portfolio
  90. 6.15.5 AbbVie Recent Developments
  91. 6.16 United Laboratory
  92. 6.16.1 United Laboratory Company Information
  93. 6.16.2 United Laboratory Business Overview
  94. 6.16.3 United Laboratory Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 United Laboratory Innovations in Biologics and Biosimilars Product Portfolio
  96. 6.16.5 United Laboratory Recent Developments
  97. 6.17 Innovent Biologics
  98. 6.17.1 Innovent Biologics Company Information
  99. 6.17.2 Innovent Biologics Business Overview
  100. 6.17.3 Innovent Biologics Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Innovent Biologics Innovations in Biologics and Biosimilars Product Portfolio
  102. 6.17.5 Innovent Biologics Recent Developments
  103. 6.18 Gan&Lee
  104. 6.18.1 Gan&Lee Company Information
  105. 6.18.2 Gan&Lee Business Overview
  106. 6.18.3 Gan&Lee Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Gan&Lee Innovations in Biologics and Biosimilars Product Portfolio
  108. 6.18.5 Gan&Lee Recent Developments
  109. 6.19 Celltrion
  110. 6.19.1 Celltrion Company Information
  111. 6.19.2 Celltrion Business Overview
  112. 6.19.3 Celltrion Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Celltrion Innovations in Biologics and Biosimilars Product Portfolio
  114. 6.19.5 Celltrion Recent Developments
  115. 6.20 3SBIO
  116. 6.20.1 3SBIO Company Information
  117. 6.20.2 3SBIO Business Overview
  118. 6.20.3 3SBIO Innovations in Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 3SBIO Innovations in Biologics and Biosimilars Product Portfolio
  120. 6.20.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Innovations in Biologics and Biosimilars Market Size (2021-2032)
  2. 7.2 North America Innovations in Biologics and Biosimilars Market Size by Type
  3. 7.2.1 North America Innovations in Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 7.2.2 North America Innovations in Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 7.2.3 North America Innovations in Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 7.3 North America Innovations in Biologics and Biosimilars Market Size by Application
  7. 7.3.1 North America Innovations in Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 7.3.2 North America Innovations in Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 7.3.3 North America Innovations in Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 7.4 North America Innovations in Biologics and Biosimilars Market Size by Country
  11. 7.4.1 North America Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Innovations in Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 7.4.3 North America Innovations in Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 7.4.4 North America Innovations in Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Innovations in Biologics and Biosimilars Market Size (2021-2032)
  2. 8.2 Europe Innovations in Biologics and Biosimilars Market Size by Type
  3. 8.2.1 Europe Innovations in Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 8.2.2 Europe Innovations in Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 8.2.3 Europe Innovations in Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 8.3 Europe Innovations in Biologics and Biosimilars Market Size by Application
  7. 8.3.1 Europe Innovations in Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 8.3.2 Europe Innovations in Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 8.3.3 Europe Innovations in Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 8.4 Europe Innovations in Biologics and Biosimilars Market Size by Country
  11. 8.4.1 Europe Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Innovations in Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 8.4.3 Europe Innovations in Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 8.4.4 Europe Innovations in Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Innovations in Biologics and Biosimilars Market Size (2021-2032)
  2. 9.2 China Innovations in Biologics and Biosimilars Market Size by Type
  3. 9.2.1 China Innovations in Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 9.2.2 China Innovations in Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 9.2.3 China Innovations in Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 9.3 China Innovations in Biologics and Biosimilars Market Size by Application
  7. 9.3.1 China Innovations in Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 9.3.2 China Innovations in Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 9.3.3 China Innovations in Biologics and Biosimilars Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Innovations in Biologics and Biosimilars Market Size (2021-2032)
  2. 10.2 Asia Innovations in Biologics and Biosimilars Market Size by Type
  3. 10.2.1 Asia Innovations in Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 10.2.2 Asia Innovations in Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 10.2.3 Asia Innovations in Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 10.3 Asia Innovations in Biologics and Biosimilars Market Size by Application
  7. 10.3.1 Asia Innovations in Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 10.3.2 Asia Innovations in Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 10.3.3 Asia Innovations in Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 10.4 Asia Innovations in Biologics and Biosimilars Market Size by Country
  11. 10.4.1 Asia Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Innovations in Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 10.4.3 Asia Innovations in Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 10.4.4 Asia Innovations in Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Innovations in Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst